Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 21;22:281. doi: 10.1186/s12933-023-02012-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Association of SHR and all-cause mortality among U.S and Chinese patients with critical AMI (A) SHR and all-cause mortality at 1-year follow-up in U.S MIMIC-IV cohort. (B) SHR and all-cause mortality at 1-year follow-up in Chinese CIN-II cohort. (C) SHR and all-cause mortality at a maximum follow-up of 12.1 years American MIMIC-IV cohort. (D) SHR and all-cause mortality at a maximum follow-up of 14.1 years in Chinese CIN-II cohort. Both cohorts adjusted for age, gender, hypertension, diabetes mellitus, congestive heart failure, chronic kidney disease, atrial fibrillation, stroke, anemia, and revascularization. HRs and 95% CIs are indicated by red lines for MIMIC-IV cohort, and by blue lines for CIN-II cohort. Density plot are presented by orange shadow area for MIMIC-IV cohort, and by light blue shadow area for CIN-II cohort. Ref = reference value